Kenneth Galbraith, Zymeworks CEO

Zymeworks adds a clas­sic poi­son pill de­fense to the ar­mory as the biotech's board bat­tles hos­tile takeover

Zymeworks $ZYME is pulling out all the stops as it looks to wrig­gle out of a hos­tile takeover ef­fort.

A few days ago, Zymeworks CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.